Helius Medical Technologies (NASDAQ:HSDT – Get Free Report) and Pheton Holdings Ltd Class A Ordinary Shares (NASDAQ:PTHL – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.
Analyst Recommendations
This is a breakdown of current ratings for Helius Medical Technologies and Pheton Holdings Ltd Class A Ordinary Shares, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Helius Medical Technologies | 0 | 1 | 0 | 0 | 2.00 |
Pheton Holdings Ltd Class A Ordinary Shares | 0 | 0 | 0 | 0 | 0.00 |
Insider & Institutional Ownership
Valuation & Earnings
This table compares Helius Medical Technologies and Pheton Holdings Ltd Class A Ordinary Shares”s revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Helius Medical Technologies | $502,000.00 | 3.54 | -$8.85 million | ($6.18) | -0.08 |
Pheton Holdings Ltd Class A Ordinary Shares | $572,291.00 | 24.84 | N/A | N/A | N/A |
Pheton Holdings Ltd Class A Ordinary Shares has higher revenue and earnings than Helius Medical Technologies.
Profitability
This table compares Helius Medical Technologies and Pheton Holdings Ltd Class A Ordinary Shares’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Helius Medical Technologies | -1,764.74% | -244.82% | -127.10% |
Pheton Holdings Ltd Class A Ordinary Shares | N/A | N/A | N/A |
Summary
Pheton Holdings Ltd Class A Ordinary Shares beats Helius Medical Technologies on 5 of the 8 factors compared between the two stocks.
About Helius Medical Technologies
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.
About Pheton Holdings Ltd Class A Ordinary Shares
Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded on November 2, 2022 and is headquartered in Beijing, China.
Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.